Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B^™

Longeveron Inc. announced it received a notice of patent allowance from the United States Patent and Trademark Office for Medicinal Signaling Cells, the technology behind its lead investigational product Lomecel-BTM. The allowance impacts patients with Aging-related Frailty receiving vaccines for conditions such as COVID and the flu.